Literature DB >> 20199241

Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.

Lee H Harrison1, Kathleen A Shutt, Susanna E Schmink, Jane W Marsh, Brian H Harcourt, Xin Wang, Anne M Whitney, David S Stephens, Amanda A Cohn, Nancy E Messonnier, Leonard W Mayer.   

Abstract

BACKGROUND: A quadrivalent meningococcal conjugate vaccine (MCV4) was licensed in the United States in 2005; no serogroup B vaccine is available. Neisseria meningitidis changes its capsular phenotype through capsular switching, which has implications for vaccines that do not protect against all serogroups.
METHODS: Meningococcal isolates from 10 Active Bacterial Core surveillance sites from 2000 through 2005 were analyzed to identify changes occurring after MCV4 licensure. Isolates were characterized by multilocus sequence typing (MLST) and outer membrane protein gene sequencing. Isolates expressing capsular polysaccharide different from that associated with the MLST lineage were considered to demonstrate capsular switching.
RESULTS: Among 1160 isolates, the most common genetic lineages were the sequence type (ST)-23, ST-32, ST-11, and ST-41/44 clonal complexes. Of serogroup B and Y isolates, 8 (1.5%) and 3 (0.9%), respectively, demonstrated capsular switching, compared with 36 (12.9%) for serogroup C (P < .001); most serogroup C switches were from virulent serogroup B and/or serogroup Y lineages.
CONCLUSIONS: A limited number of genetic lineages caused the majority of invasive meningococcal infections. A substantial proportion of isolates had evidence of capsular switching. The high prevalence of capsular switching requires surveillance to detect changes in the meningococcal population structure that may affect the effectiveness of meningococcal vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199241      PMCID: PMC2838939          DOI: 10.1086/651505

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

Review 1.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

2.  Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain.

Authors:  M Diermayer; K Hedberg; F Hoesly; M Fischer; B Perkins; M Reeves; D Fleming
Journal:  JAMA       Date:  1999-04-28       Impact factor: 56.272

3.  Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Authors:  Daniel A Scott; Steven F Komjathy; Branda T Hu; Sherryl Baker; Lois A Supan; Carol A Monahan; William Gruber; George R Siber; Stephen P Lockhart
Journal:  Vaccine       Date:  2007-06-26       Impact factor: 3.641

Review 4.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Differential distribution of novel restriction-modification systems in clonal lineages of Neisseria meningitidis.

Authors:  H Claus; A Friedrich; M Frosch; U Vogel
Journal:  J Bacteriol       Date:  2000-03       Impact factor: 3.490

6.  Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.

Authors:  Rekha Pai; Matthew R Moore; Tamara Pilishvili; Robert E Gertz; Cynthia G Whitney; Bernard Beall
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

7.  Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada.

Authors:  Raymond Sw Tsang; Dennis Ks Law; Shaun D Tyler; Gwen S Stephens; Mark Bigham; Wendell D Zollinger
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

8.  Active bacterial core surveillance of the emerging infections program network.

Authors:  A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

9.  Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis.

Authors:  Elizabeth A Mothershed; Claudio T Sacchi; Anne M Whitney; Gwen A Barnett; Gloria W Ajello; Susanna Schmink; Leonard W Mayer; Maureen Phelan; Thomas H Taylor; Scott A Bernhardt; Nancy E Rosenstein; Tanja Popovic
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

10.  mlstdbNet - distributed multi-locus sequence typing (MLST) databases.

Authors:  Keith A Jolley; Man-Suen Chan; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2004-07-01       Impact factor: 3.169

View more
  44 in total

1.  Invasive meningococcal disease caused by Neisseria meningitidis strains expressing both serogroup Y and W-135 antigenic specificities.

Authors:  Karen M Rudolph; Carolynn DeByle; Alisa Reasonover; Tammy Zulz; Dennis K S Law; Jianwei Zhou; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

2.  Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Authors:  C Hal Jones; Naglaa Mohamed; Eduardo Rojas; Lubomira Andrew; Johanna Hoyos; Julio C Hawkins; Lisa K McNeil; Qin Jiang; Leonard W Mayer; Xin Wang; Rodica Gilca; Philippe De Wals; Louise Pedneault; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

Review 3.  Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.

Authors:  Amy C Sherman; David S Stephens
Journal:  Expert Rev Vaccines       Date:  2020-04-29       Impact factor: 5.217

4.  Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008.

Authors:  Mignon du Plessis; Chivonne Moodley; Kedibone M Mothibeli; Azola Fali; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

5.  Neisseria meningitidis disease-associated clones in Amazonas State, Brazil.

Authors:  Luciete A Silva; Beatriz Coronato; Jessica Schlackman; Jane W Marsh; Chinelo Ezeonwuka; Andréia C L Fernandes; Victor C Souza; Lirna S da Silva; Elaine F Q de Amorim; Felipe G Naveca; Bernardino C de Albuquerque; Alcirene Amaral; Ana L S Souza; Filipe A Carvalho-Costa; Mustapha M Mustapha; Lee H Harrison; David E Barroso
Journal:  Infect Dis (Lond)       Date:  2018-04-06

Review 6.  Regulation of capsule in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Jennifer Thomas; David S Stephens
Journal:  Crit Rev Microbiol       Date:  2015-06-19       Impact factor: 7.624

Review 7.  Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.

Authors:  Mustapha M Mustapha; Lee H Harrison
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

8.  Meningococcal serogroup Y emergence in Europe: update 2011.

Authors:  Michael Bröker; Susanne Jacobsson; Markku Kuusi; David Pace; Maria J Simões; Anna Skoczynska; Muhamed-Kheir Taha; Maija Toropainen; Georgina Tzanakaki
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

9.  Genomic basis of a polyagglutinating isolate of Neisseria meningitidis.

Authors:  Lavanya Rishishwar; Lee S Katz; Nitya V Sharma; Lori Rowe; Michael Frace; Jennifer Dolan Thomas; Brian H Harcourt; Leonard W Mayer; I King Jordan
Journal:  J Bacteriol       Date:  2012-08-17       Impact factor: 3.490

10.  The capsule polymerase CslB of Neisseria meningitidis serogroup L catalyzes the synthesis of a complex trimeric repeating unit comprising glycosidic and phosphodiester linkages.

Authors:  Christa Litschko; Maria Rosaria Romano; Vittoria Pinto; Heike Claus; Ulrich Vogel; Francesco Berti; Rita Gerardy-Schahn; Timm Fiebig
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.